San Francisco-Rio de Janeiro collaborative research on HIV prevalence, risk, and biomedical prevention interventions among young men who have sex with men
旧金山-里约热内卢合作研究男男性行为青年中的艾滋病毒患病率、风险和生物医学预防干预措施
基本信息
- 批准号:10593960
- 负责人:
- 金额:$ 11.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-10 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAcuteAddressAdherenceAgeAmericanBiological MarkersBiomedical ResearchBlack raceBrazilCD4 Lymphocyte CountCaliforniaCaringCitiesClinicalClinical TrialsCollaborationsCross-Sectional StudiesDetectionDevelopmentDiagnosisDisparityDropsEffectivenessEpidemicEthicsFaceFoundationsFutureHIVHIV InfectionsHIV SeronegativityHIV diagnosisHealthHealth ServicesIncidenceInfectionInterruptionInterventionInvestigationInvestmentsJointsKnowledgeLinkMeasuresMethodsMinorMinority MenOutcomeParentsParticipantPatientsPersonsPhylogenetic AnalysisPoliciesPopulationPrevalencePrevention ResearchPrevention programProviderPublic HealthRNARaceReportingResearchResearch PersonnelResourcesRespondentRiskRisk BehaviorsSamplingSan FranciscoScientistSexual HealthSexually Transmitted DiseasesSouth AmericaSurveysTechnologyTestingUnited States National Institutes of HealthViralViral Load resultacute infectionblack men who have sex with menexperienceimprovedinnovationintervention programlow and middle-income countriesmen who have sex with mennovel strategiespilot testpopulation basedpre-exposure prophylaxispreventpreventive interventionprogramsracial disparityrapid diagnosisscale upsocial mediasuccesstranslational frameworktransmission processuptakeyoung manyoung men who have sex with men
项目摘要
ABSTRACT
As San Francisco’s HIV epidemic is set to reach zero infections, Rio de Janeiro is experiencing
a resurgence in new reported HIV cases among MSM. San Francisco’s success can be
attributed to effective biomedical interventions, namely: rapid diagnosis, immediate ART,
sustained viral load suppression, wide uptake of PrEP, and interrupting new clusters of
transmission. In Brazil, however, uptake of these biomedical interventions has so far been
insufficient to reverse the epidemic, despite being the first low/middle income country to provide
free ART to all persons with HIV, participation in clinical trials proving PrEP efficacy, and
national policy to provide free PrEP. Meanwhile, young MSM, particularly Black/Afro-Brazilians,
have high HIV incidence, low viral suppression, and poor PrEP adherence. We therefore
propose collaborative research between the San Francisco Department of Public Health and the
Oswaldo Cruz Foundation (Fiocruz) in Rio de Janeiro. We will focus on identifying the drivers of
HIV infection, ways to address barriers to biomedical interventions, and identifying the hurdles
to including young MSM in biomedical research. Methods include a cross-sectional survey of
MSM age 18-24 using respondent-driven sampling adapted for social media-based sampling;
development of a technology-based rapid ART and PrEP engagement and retention
intervention; and a qualitative study of MSM age 15-17, their parents, and providers of sexual
health services to better understand the onset of risk and the feasibility of increasing inclusion of
minors in biomedical HIV research and intervention programs. San Francisco stands as an
American test case for the elimination of HIV, yet remaining challenges exist in reaching young
and minority MSM. Rio de Janeiro is an engine of HIV research in South America, yet faces
challenges in reaping the benefit of proven biomedical interventions for MSM. The proposed
US-Brazil research collaboration will provide mutual benefit in increasing the effectiveness of
biomedical interventions to reverse the HIV epidemic among MSM in Brazil and address
remaining disparities in the US.
摘要
随着旧金山弗朗西斯科的艾滋病疫情将达到零感染,里约热内卢正在经历
男男性行为者中新报告的艾滋病毒病例有所回升。弗朗西斯科的成功
这归功于有效的生物医学干预措施,即:快速诊断,立即抗逆转录病毒疗法,
持续的病毒载量抑制,广泛吸收PrEP,并中断新的集群,
传输然而,在巴西,迄今为止,这些生物医学干预措施的采用
尽管是第一个提供援助的低/中等收入国家,
向所有艾滋病毒感染者提供免费抗逆转录病毒治疗,参与证明PrEP疗效的临床试验,以及
同时,年轻的男男性接触者,特别是黑人/非洲裔巴西人,
HIV发病率高,病毒抑制率低,PrEP依从性差。因此我们
建议在旧金山弗朗西斯科公共卫生部和
Oswaldo Cruz Foundation(Fiocruz)in Rio de Janeiro.我们将集中精力确定
艾滋病毒感染、消除生物医学干预障碍的方法以及确定障碍
将年轻的男男性接触者纳入生物医学研究。方法包括一个横断面调查,
18-24岁男男性接触者,采用基于社交媒体的抽样,采用受访者驱动的抽样;
开发基于技术的快速ART和PrEP参与和保留
干预;以及对15-17岁的MSM,他们的父母和性服务提供者的定性研究
卫生服务,以更好地了解风险的发生和增加包容性的可行性,
未成年人在生物医学艾滋病毒研究和干预方案。旧金山弗朗西斯科是
美国消除艾滋病毒的测试案例,但在接触年轻人方面仍然存在挑战
少数的MSM里约热内卢是南美洲艾滋病研究的引擎,但面临着
在获得经证实的男男性行为者生物医学干预措施的好处方面面临的挑战。拟议
美国与巴西的研究合作将在提高
采取生物医学干预措施,以扭转巴西男男性行为者中艾滋病毒的流行,
在美国仍然存在差距。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Correction to: The Prevalence of HIV Among Men Who Have Sex With Men (MSM) and Young MSM in Latin America and the Caribbean: A Systematic Review.
更正:拉丁美洲和加勒比地区男男性行为者 (MSM) 和年轻 MSM 中艾滋病毒的流行情况:系统回顾。
- DOI:10.1007/s10461-021-03400-y
- 发表时间:2022
- 期刊:
- 影响因子:4.4
- 作者:Coelho,LaraE;Torres,ThiagoS;Veloso,ValdileaG;Grinsztejn,Beatriz;Jalil,EmiliaM;Wilson,ErinC;McFarland,Willi
- 通讯作者:McFarland,Willi
Interpersonal Violence and Passing: Results from a Brazilian Trans-specific Cross-sectional Study.
人际暴力和传递:巴西跨性别者横断面研究的结果。
- DOI:10.1177/08862605211005152
- 发表时间:2022
- 期刊:
- 影响因子:2.5
- 作者:Peixoto,EduardoMesquita;deAzevedoOliveiraKnupp,VirginiaMaria;Soares,JesilaineResendeTeixeira;Depret,DaviGomes;deOliveiraSouza,Cleo;Messina,MariaEduardaDantas;deMelloAndrade,LíviaMachado;deMelo,LucianaCatarinaSantos;deFig
- 通讯作者:deFig
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BEATRIZ GRINSZTEJN其他文献
BEATRIZ GRINSZTEJN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BEATRIZ GRINSZTEJN', 18)}}的其他基金
San Francisco-Rio de Janeiro collaborative research on HIV prevalence, risk, and biomedical prevention interventions among young men who have sex with men
旧金山-里约热内卢合作研究男男性行为青年中的艾滋病毒患病率、风险和生物医学预防干预措施
- 批准号:
10375409 - 财政年份:2020
- 资助金额:
$ 11.05万 - 项目类别:
San Francisco-Rio de Janeiro collaborative research on HIV prevalence, risk, and biomedical prevention interventions among young men who have sex with men
旧金山-里约热内卢合作研究男男性行为青年中的艾滋病毒患病率、风险和生物医学预防干预措施
- 批准号:
9888943 - 财政年份:2020
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位 (FioTrials)
- 批准号:
8208878 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位 (FioTrials)
- 批准号:
8415479 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位
- 批准号:
8609412 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit.
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位。
- 批准号:
10531198 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位 (FioTrials)
- 批准号:
8010948 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位
- 批准号:
9181371 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位 (FioTrials)
- 批准号:
7095666 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)
FIOCRUZ 治疗和预防艾滋病毒/艾滋病临床试验单位 (FioTrials)
- 批准号:
7555625 - 财政年份:2008
- 资助金额:
$ 11.05万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 11.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 11.05万 - 项目类别:
Operating Grants